Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX)
Study sponsor: DiaMedica Therapeutics Inc · DMAC
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-03-16Actual
Enrollment · participants84Actual
Source updated2026-11-10Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.